{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:12:34Z","timestamp":1776737554625,"version":"3.51.2"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Marginal zone lymphoma (MZL) is the second most common subtype of inert B-cell non-Hodgkin\u2019s lymphoma, accounting for 5\u201315% of non-Hodgkin\u2019s lymphoma cases. Patients with MZL have a long survival period, with a median survival of &amp;gt;10 years, and patients treated with a combination of anti-CD20 monoclonal antibody can achieve an overall effective rate of 81%. However, 20% of patients with MZL show relapse or experience disease progression within 2 years, with a median survival of only 3\u20135 years. Currently, the treatment options for patients with relapsed\/refractory (R\/R) MZL are limited, underscoring the pressing need for novel therapeutic drugs. The advent of novel anti-CD20 monoclonal antibodies, small molecule kinase inhibitors, immunomodulators, and other therapeutic strategies has ushered in a new era in the treatment of R\/R MZL. Our objective is to summarize the existing treatment strategies, including immunotherapy and the emergent targeted therapies, and to evaluate their effectiveness and safety in the management of R\/R MZL. By doing so, we aim to provide a clear understanding of the therapeutic landscape for R\/R MZL, and to guide future research directions toward improving the prognosis and quality of life for patients afflicted with this challenging disease.<\/jats:p>","DOI":"10.3389\/fonc.2024.1327309","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:30:51Z","timestamp":1706157051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in the treatment of relapsed\/refractory marginal zone lymphoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Haotian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.12730","article-title":"Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site","volume":"165","author":"Khalil","year":"2014","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pathol.2019.08.012","article-title":"Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches","volume":"52","author":"Nakamura","year":"2020","journal-title":"Pathology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040547","article-title":"Novel insights of lymphomagenesis of helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma","volume":"11","author":"Kuo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.beha.2017.01.001","article-title":"Bacteria associated with marginal zone lymphomas","volume":"30","author":"Ponzoni","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010176","article-title":"Recent advances in the genetic of MALT lymphomas","volume":"14","author":"Rodr\u00edguez-Sevilla","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1097\/hs9.0000000000000699","article-title":"Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial","volume":"6","author":"Herold","year":"2022","journal-title":"Hemasphere"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1182\/blood-2023-186626","article-title":"Cumulative incidence, predictors, and outcomes of transformation to diffuse large B-cell lymphoma in a prospective cohort of patients with marginal zone lymphoma","volume":"142","author":"Bommier","year":"2023","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-023-01448-y","article-title":"Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010133","article-title":"Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26715","article-title":"Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma","volume":"97","author":"Alderuccio","year":"2022","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell Malignancies: current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological Malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.12688\/f1000research.13826.1","article-title":"Recent advances in understanding the biology of marginal zone lymphoma","volume":"7","author":"Bertoni","year":"2018","journal-title":"F1000Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-022-01316-1","article-title":"Predictive factors and outcomes for ibrutinib in relapsed\/refractory marginal zone lymphoma: a multicenter cohort study","volume":"15","author":"Epperla","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/bloodadvances.2022008634","article-title":"Postibrutinib relapse outcomes for patients with marginal zone lymphoma","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27064","article-title":"Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study","volume":"98","author":"Deng","year":"2023","journal-title":"Am J Hematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11864-020-00746-8","article-title":"PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma","volume":"21","author":"Sapon-Cousineau","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03f5 Inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1208170","article-title":"Lenalidomide for the treatment of B-cell lymphoma","volume":"25","author":"Garciaz","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.10.018","article-title":"Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the\u00a0United States of America: A population-based cohort study","volume":"70","author":"Luo","year":"2017","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv102","article-title":"A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma","volume":"26","author":"Witzig","year":"2015","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_138","article-title":"PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA","volume":"35","author":"Coleman","year":"2017","journal-title":"Hematological Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00010","article-title":"AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009412","article-title":"Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma","volume":"7","author":"Tatarczuch","year":"2023","journal-title":"Blood Adv"},{"key":"B58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood.2022018674","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106577","article-title":"Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship","volume":"138","author":"Wang","year":"2023","journal-title":"Bioorg Chem"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-1272","article-title":"FDA approval summary: pirtobrutinib for relapsed or refractory mantle cell lymphoma","volume":"30","author":"Telaraja","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01860-1","article-title":"Pirtobrutinib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/s0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell Malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180048","article-title":"Pirtobrutinib, a highly selective, non-covalent (Reversible) BTK inhibitor in relapsed \/ refractory marginal zone lymphoma: results from phase 1\/2 BRUIN study","volume":"142","author":"Patel","year":"2023","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2016.06.001","article-title":"Functional Implications of the spectrum of BCL2 mutations in Lymphoma","volume":"769","author":"Singh","year":"2016","journal-title":"Mutat Res Rev Mutat Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-171046","article-title":"A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of bcl-2 inhibitor bgb-11417 in adult patients with mature B-cell Malignancies: preliminary data","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178841","article-title":"Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed\/refractory marginal zone lymphoma: data from an ongoing phase 1 study","volume":"142","author":"Tedeschi","year":"2023","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2013.05.002","article-title":"The histone LSD1 demethylase in stemness and cancer transcription programs","volume":"1829","author":"Amente","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00978","article-title":"Discovery of CC-90011: A potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1)","volume":"63","author":"Kanouni","year":"2020","journal-title":"J Med Chem"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34366","article-title":"Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced Malignancies","volume":"128","author":"Hollebecque","year":"2022","journal-title":"Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-018-9411-4","article-title":"Genetic engineering of T cells with chimeric antigen receptors for hematological Malignancy immunotherapy","volume":"61","author":"Ti","year":"2018","journal-title":"Sci China Life Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681984","article-title":"A deep insight into CAR-T cell therapy in non-hodgkin lymphoma: application, opportunities, and future directions","volume":"12","author":"Marofi","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1634\/theoncologist.2020-0559","article-title":"CAR T-cell therapy shows durable responses in indolent NHL","year":"2020","journal-title":"Oncologist"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174914","article-title":"Axicabtagene ciloleucel (Axi-cel) in patients with relapsed\/refractory indolent non-hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-023-01488-4","article-title":"CD20 \u00d7 CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A\u00a0phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180473","article-title":"Marsun, a phase III, multicenter, open label, randomized, controlled study investigating mosunetuzumab-lenalidomide versus investigator choices in patients with relapsed or refractory marginal zone lymphoma (R\/R MZL)","volume":"142","author":"Thieblemont","year":"2023","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35072","article-title":"The genetic landscape of histologically transformed marginal zone lymphomas","author":"Li","year":"2023","journal-title":"Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12633","article-title":"Genetic landscape and deregulated pathways in B-cell lymphoid Malignancies","volume":"282","author":"Rosenquist","year":"2017","journal-title":"J Intern Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010253","article-title":"Histone modifications and their targeting in lymphoid Malignancies","volume":"23","author":"Fern\u00e1ndez-Serrano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-051122-100856","article-title":"Epigenomic characterization of lymphoid neoplasms","author":"Duran-Ferrer","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009415","article-title":"Unraveling the genetics of transformed splenic marginal zone lymphoma","volume":"7","author":"Grau","year":"2023","journal-title":"Blood Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1327309\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:30:55Z","timestamp":1706157055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1327309\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":87,"alternative-id":["10.3389\/fonc.2024.1327309"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1327309","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"article-number":"1327309"}}